# Optimizing Anti-IL17 Antibody Therapy by Associating Fiber Supplementation to Correct Treatment-aggravated Gut Dysbiosis in Axial Spondyloarthritis - RESPOND-IL17

> **NCT05812157** · NA · RECRUITING · sponsor: **Centre Hospitalier Universitaire de Nīmes** · enrollment: 36 (estimated)

## Conditions studied

- Axial Spondyloarthritis

## Interventions

- **DIETARY_SUPPLEMENT:** Daily dietary supplementation with Fibruline
- **DRUG:** Anti-IL-17 therapy

## Key facts

- **NCT ID:** NCT05812157
- **Lead sponsor:** Centre Hospitalier Universitaire de Nīmes
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2023-10-02
- **Primary completion:** 2026-12-01
- **Final completion:** 2026-12-01
- **Target enrollment:** 36 (ESTIMATED)
- **Last updated:** 2025-05-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05812157

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05812157, "Optimizing Anti-IL17 Antibody Therapy by Associating Fiber Supplementation to Correct Treatment-aggravated Gut Dysbiosis in Axial Spondyloarthritis - RESPOND-IL17". Retrieved via AI Analytics 2026-06-26 from https://api.ai-analytics.org/clinical/NCT05812157. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*